How to use ibrutinib

How to use ibrutinib

The emergence of new targeted drugs, affecting B-cell receptor signaling pathway opens a new page in the treatment of chronic lymphocytic leukemia (CLL). It is not simply expanding choice, it will likely to change total strategy of CLL management. Clinical trials have shown improvement of overall su...

Full description

Bibliographic Details
Main Authors:	Е. А. Nikitin, V. I. Vorobiev, М. А. Panteleev, G. E. Gendlin, V. V. Ptushkin
Format:	Article
Language:	Russian
Published:	ABV-press 2017-04-01
Series:	Onkogematologiâ
Subjects:	chronic lymphocytic leukemia targeted drugs ibrutini
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/229

Similar Items

Rhythm and Conduction Disorders in Patients Receiving Ibrutinib
by: EI Emelina, et al.
Published: (2019-03-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

Infections in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib: Incidence and Predisposing Factors
by: EA Dmitrieva, et al.
Published: (2019-09-01)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)

Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib
by: EI Emelina, et al.
Published: (2019-09-01)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
by: Timothy L. Chen, et al.
Published: (2021-02-01)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by: Francesca Romana Mauro, et al.
Published: (2021-06-01)

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients
by: NV Kurkina, et al.
Published: (2019-05-01)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
by: Maria Cristina Puzzolo, et al.
Published: (2021-04-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Ferrarini, I., et al.
Published: (2022)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder
by: Daniel Rivera, et al.
Published: (2021-06-01)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
by: Peter Georgantopoulos, et al.
Published: (2019-05-01)

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
by: Simon Schliffke, et al.
Published: (2018-04-01)

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: Lorenzo Falchi, et al.
Published: (2016-02-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)

Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Developing Methods and Targeted Therapeutics to Address Complications of Ibrutinib Treatment in Chronic Lymphocytic Leukemia
by: Hu, Eileen Yifan
Published: (2020)

Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017
by: Stefano Molica
Published: (2017-08-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
by: Ayad M. Al‐Katib, et al.
Published: (2020-09-01)

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution
by: Irina V. Poddubnaya, et al.
Published: (2020-05-01)

Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report
by: Thuy-Hong Le, et al.
Published: (2020-02-01)

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
by: David E. Spaner, et al.
Published: (2019-04-01)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
by: Zhou H, et al.
Published: (2020-05-01)

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib
by: Fady Gh Haddad, et al.
Published: (2021-01-01)

Ibrutinib-induced acute kidney injury via interstitial nephritis
by: Csilla Markóth, et al.
Published: (2021-01-01)

Overview of recent developments in chronic lymphocytic leukemia
by: Preetesh Jain, et al.
Published: (2012-01-01)

From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct
by: Isabel González-Gascón-y-Marín, et al.
Published: (2021-04-01)

Biclonal chronic lymphocytic leukemia: A study of two cases and review of literature
by: Kiran Ashok Ghodke, et al.
Published: (2017-01-01)

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
by: Babina Gosangi, et al.
Published: (2018-04-01)

Utilizing Reversible Bruton’s Tyrosine Kinase Inhibitors to Circumvent Acquired Resistance to Ibrutinib
by: Reiff, Sean
Published: (2018)

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
by: Samip Master, et al.
Published: (2017-06-01)

Precision Medicine Management of Chronic Lymphocytic Leukemia
by: Riccardo Moia, et al.
Published: (2020-03-01)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
by: Maurizio Cavallari, et al.
Published: (2017-01-01)

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
by: Yamit Shorer Arbel, et al.
Published: (2021-05-01)

THE USE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE COMPLICATIONS OF CHRONIC LYMPHOCYTIC LEUKEMIA
by: Luca Laurenti
Published: (2013-04-01)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
by: Katherine R. Sittig, et al.
Published: (2021-01-01)

Prospective analysis of efficacy and safety of BR regime in the first-line treatment of chronic lymphocytic leukemia
by: E A Stadnik, et al.
Published: (2016-12-01)

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
by: Damjan Avsec, et al.
Published: (2021-09-01)